233 related articles for article (PubMed ID: 16990649)
1. A perspective view of sodium iodide symporter research and its clinical implications.
Riesco-Eizaguirre G; Santisteban P
Eur J Endocrinol; 2006 Oct; 155(4):495-512. PubMed ID: 16990649
[TBL] [Abstract][Full Text] [Related]
2. [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].
Spitzweg C
Internist (Berl); 2003 Apr; 44(4):396-402, 404-8, 410-1. PubMed ID: 12914397
[TBL] [Abstract][Full Text] [Related]
3. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond.
Dohán O; Carrasco N
Mol Cell Endocrinol; 2003 Dec; 213(1):59-70. PubMed ID: 15062574
[TBL] [Abstract][Full Text] [Related]
4. The sodium iodide symporter: its pathophysiological and therapeutic implications.
Spitzweg C; Morris JC
Clin Endocrinol (Oxf); 2002 Nov; 57(5):559-74. PubMed ID: 12390328
[TBL] [Abstract][Full Text] [Related]
5. [The practical relevance of the sodium iodide symporter].
Spitzweg C
Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():25-32. PubMed ID: 15255310
[TBL] [Abstract][Full Text] [Related]
6. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance.
Dohán O; De la Vieja A; Paroder V; Riedel C; Artani M; Reed M; Ginter CS; Carrasco N
Endocr Rev; 2003 Feb; 24(1):48-77. PubMed ID: 12588808
[TBL] [Abstract][Full Text] [Related]
7. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
Carvalho DP; Ferreira AC
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
[TBL] [Abstract][Full Text] [Related]
8. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
[TBL] [Abstract][Full Text] [Related]
9. Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells.
Dohán O; De la Vieja A; Carrasco N
Mol Endocrinol; 2006 May; 20(5):1121-37. PubMed ID: 16439463
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
11. Sodium iodide symporter in health and disease.
Shen DH; Kloos RT; Mazzaferri EL; Jhian SM
Thyroid; 2001 May; 11(5):415-25. PubMed ID: 11396700
[TBL] [Abstract][Full Text] [Related]
12. Sodium iodide symporter: its role in nuclear medicine.
Chung JK
J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
[TBL] [Abstract][Full Text] [Related]
13. Sodium iodide symporter-based strategies for diagnosis and treatment of thyroidal and nonthyroidal malignancies.
Heufelder AE; Morgenthaler N; Schipper ML; Joba W
Thyroid; 2001 Sep; 11(9):839-47. PubMed ID: 11575853
[TBL] [Abstract][Full Text] [Related]
14. Implications of the molecular characterization of the sodium-iodide symporter (NIS).
Schmutzler C; Köhrle J
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 3():S1-10. PubMed ID: 9865544
[TBL] [Abstract][Full Text] [Related]
15. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.
Ravera S; Reyna-Neyra A; Ferrandino G; Amzel LM; Carrasco N
Annu Rev Physiol; 2017 Feb; 79():261-289. PubMed ID: 28192058
[TBL] [Abstract][Full Text] [Related]
16. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.
Kogai T; Brent GA
Pharmacol Ther; 2012 Sep; 135(3):355-70. PubMed ID: 22750642
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology.
De La Vieja A; Dohan O; Levy O; Carrasco N
Physiol Rev; 2000 Jul; 80(3):1083-105. PubMed ID: 10893432
[TBL] [Abstract][Full Text] [Related]
18. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid.
Wapnir IL; Goris M; Yudd A; Dohan O; Adelman D; Nowels K; Carrasco N
Clin Cancer Res; 2004 Jul; 10(13):4294-302. PubMed ID: 15240514
[TBL] [Abstract][Full Text] [Related]
19. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
Spitzweg C; Baker CH; Bergert ER; O'Connor MK; Morris JC
Hum Gene Ther; 2007 Oct; 18(10):916-24. PubMed ID: 17931047
[TBL] [Abstract][Full Text] [Related]
20. Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer.
Knostman KA; Cho JY; Ryu KY; Lin X; McCubrey JA; Hla T; Liu CH; Di Carlo E; Keri R; Zhang M; Hwang DY; Kisseberth WC; Capen CC; Jhiang SM
J Clin Endocrinol Metab; 2004 Oct; 89(10):5196-203. PubMed ID: 15472226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
